Prot #DV3-LYM-01: A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date2/13/152/13/18

Funding

  • Dynavax Technologies Corporation (Prot #DV3-LYM-01)